


```

Query Match          92.08; Score 55.2; DB 6; Length 1608;
Best Local Similarity 95.09; E-val: No. 7.4e-06;
Matches 57; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 gacatcaagcagggcccaatgagcccttcagcactacgtgagccgcttcttcaagacc 60
||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| |||||||
DB 466 GACATCAAGCAGGGCCCAATGAGCCCTTCAGCACTACGTGAGCCGCTTCTTCAAGACC 525

RESULT 2
LOCUS AX188560 1914 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 31 from Patent WO0147955.
ACCESSION AX188560
VERSION AX188560.1 GI:15142200
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
artificial sequence.
REFERENCE
1 (bases 1 to 1914)
Hanke,T.M. and Menichaeal,A.J.
Improvements in or relating to immune responses to hiv
Patent: WO 0147955-A 31 05 JUL 2001;
MEDICAL RESEARCH COUNCIL (GB) ; International Aids Vaccine
Initiative (US) ; University of Nairobi (KE)
FEATURES
Location/Qualifiers
source
1..1914
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Chimeric polynucleotide"
BASE COUNT 383 a 728 c 534 g 269 +
ORIGIN
1
Query Match          92.08; Score 55.2; DB 6; Length 1614;
Best Local Similarity 95.09; E-val: No. 7.3e-06;
Matches 57; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 gacatcaagcagggcccaatgagcccttcagcactacgtgagccgcttcttcaagacc 60
||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| |||||||
DB 466 GACATCAAGCAGGGCCCAATGAGCCCTTCAGCACTACGTGAGCCGCTTCTTCAAGACC 525

RESULT 3
LOCUS AX188562 3493 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 31 from Patent WO0147955.
ACCESSION AX188562
VERSION AX188562.1 GI:15142201
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
artificial sequence.
REFERENCE
1 (bases 1 to 3493)
Hanke,T.M. and Menichaeal,A.J.
Improvements in or relating to immune responses to hiv
Patent: WO 0147955-A 31 05 JUL 2001;
MEDICAL RESEARCH COUNCIL (GB) ; International Aids Vaccine
Initiative (US) ; University of Nairobi (KE)
FEATURES
Location/Qualifiers
source
1..3493
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Chimeric polynucleotide"
BASE COUNT 516 a 887 c 685 g 465 +
ORIGIN
1
Query Match          92.08; Score 55.2; DB 6; Length 1608;
Best Local Similarity 95.09; E-val: No. 7e-06;
Matches 57; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 gacatcaagcagggcccaatgagcccttcagcactacgtgagccgcttcttcaagacc 60
||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| |||||||
DB 466 GACATCAAGCAGGGCCCAATGAGCCCTTCAGCACTACGTGAGCCGCTTCTTCAAGACC 525

RESULT 4
LOCUS AX188564 4350 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 33 from Patent WO0147955.
ACCESSION AX188564
VERSION AX188564.1 GI:15142202
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
artificial sequence.
REFERENCE
1 (bases 1 to 4350)
Hanke,T.M. and Menichaeal,A.J.
Improvements in or relating to immune responses to hiv
Patent: WO 0147955-A 31 05 JUL 2001;
MEDICAL RESEARCH COUNCIL (GB) ; International Aids Vaccine
Initiative (US) ; University of Nairobi (KE)
FEATURES
Location/Qualifiers
source
1..4350
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Chimeric polynucleotide"
BASE COUNT 898 a 1630 c 1259 g 573 t
ORIGIN
1
Query Match          92.09; Score 55.2; DB 6; Length 4350;
Best Local Similarity 95.09; E-val: No. 6.6e-06;
Matches 57; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 gacatcaagcagggcccaatgagcccttcagcactacgtgagccgcttcttcaagacc 60
||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| |||||||
DB 466 GACATCAAGCAGGGCCCAATGAGCCCTTCAGCACTACGTGAGCCGCTTCTTCAAGACC 525

RESULT 5
LOCUS AX201927 1500 bp DNA linear SYN 16-MAR-2000
DEFINITION Synthetic construct and protein gene, complete cds.
ACCESSION AX201927
VERSION AX201927.1 GI:7248702
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
artificial sequence.
REFERENCE
1 (bases 1 to 1509)
zur Hagedorn,J., Chen,M.C., Dye,R., Schaefer,M., Greer,C.E.,
Selby,M., Otten,G.R. and Barnett,S.W.
Increased expression and immunogenicity of sequence-modified human
immunodeficiency virus type 1 gag gene
J. Virol. 74 (6), 2628-2635 (2000)
JOURNAL
PUBMED 10684277
REFERENCE
2 (bases 1 to 1509)
zur Hagedorn,J. and Barnett,S.W.
Direct Submission
TITLE
Submitted (04-NOV-1999) Vaccines, Chiron Corporation, 4560 Horton,
Emeryville, CA 94608, USA
JOURNAL
FEATURES
Location/Qualifiers
source
1..1509
/organism="synthetic construct"
/db_xref="taxon:32630"
1..1509
/note="HIV-1SF2 p55gag"
/codon_start=1
/transl_table=11
/product="p55 protein"
/protein_id="AAP4328.1"
CDS
1..1509
/organism="synthetic construct"
/db_xref="taxon:32630"
1..1509
/note="HIV-1SF2 p55gag"
/codon_start=1
/transl_table=11
/product="p55 protein"
/protein_id="AAP4328.1"

```



```

RESULT 14
AX306429
LOCUS
DEFINITION
Sequence 3 from Patent WO0188141.
ACCESSION
AX306429
VERSION
AX306429.1 GI:17645653
KEYWORDS
synthetic construct.
SOURCE
synthetic construct.
ORGANISM
artificial sequence.
1 (sites)
Wagner,R., Grat,M., Deml,L. and Bieler,K.
AUTHORS
Synthetic gapped genes and their uses
TITLE
Patent: WO 0188141-A 3 22-NOV-2001:
JOURNAL
Geneart GmbH (DE)
FEATURES
Location/Qualifiers
1..4341
/organism="synthetic construct"
/DB_xref="taxon:32630"
/note="sequence with optimized codons"
BASE COUNT 1094 a 1341 c 1388 g 548 t
ORIGIN

```

```
Query Match      78.7%   Score 47.2; DB 6; Length 4341;
Best Local Similarity 86.7%   Prid.No.0.0012;
Matches 52; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
```

RESULT	15
AX306428	
LOCUS	4343 bp DNA linear
DEFINITION	Sequence 2 from Patent WO0188141.
ACCESSION	AX306428
VERSION	AX306428.1 GI:17645652
KEYWORDS	. synthetic construct. synthetic construct artificial sequence.
ORGANISM	1 (sites)
REFERENCE	Wagner,K., Graf,M., Deml,J.L. and Bieker,K.
AUTHORS	Synthetic gapoil genes and their uses
TITLE	Patent: WO 0188141-A 2 22-NOV-2001;
JOURNAL	Geneart GmbH (DE)
FEATURES	Location/Qualifiers
SOURCE	1..4343 /organism="synthetic construct" /db_xref="taxon:32630" /notes="sequence with optimized codons"
BASE COUNT	1064 a 1341 c 1388 g 550 t.
ORIGIN	

Query Match	78.7%	Score 47.2	EP 6.	Length 4343
Best Local Similarity	86.7%	Pred. No. 0.0012:		
Matches	52;	Conservative	0;	Mismatches 8; Indels 0; Gaps 0;
QY	1	qacatcaagcgggcccaccaggaccccttcgcgaactacgttgacgacctcttctcagaacc	60	
b_	850	GATATCAGSNGSGGCTTAAAGAGCTTTTCAGCAACTACCTCCACAGCTGTATTACAGAAC	909	

PR 31-DEC-1998; 9805-011449E.
 PR 01-SEP-1999; 9805-015214E.
 XX
 PA (CHIR) CHIRON CORP.
 XX Barnett L. S., Zur Meysede J;
 XX WP1: 2000-452401/39.
 DR
 PR Polynucleotide encoding antigenic type C HIV Gag polypeptide or a HIV
 PT Env polypeptide and the polypeptide useful for immunizing a human
 PT especially human against HIV
 XX
 PS Disclosure, Page 104, 113pp, English.
 XX
 CC Expression cassettes comprising a polynucleotide encoding antigenic
 CC type C human immunodeficiency virus (HIV) Gag or env polypeptides are
 CC useful in DNA immunization, penetration of packaging cell lines and
 CC production of Gag and/or Env containing particles, synthetic Env and Gag
 CC expression cassettes exhibit increased potency for induction of
 CC cytotoxic T-lymphocyte (CTL) responses by HIV immunization. Gag of HIV 1
 CC self-assemble into non infectious virus like particles which are useful
 CC as a matrix for the proper presentation of an antigen, overlapped or
 CC associated to the immune system of the host.
 XX
 SQ Sequence 1509 BP; 321 A; 559 C; 471 G; 158 T; 0 other;
 Query Match 92.0%; Score 55.2; PP 21; Length 1609;
 Best Local Similarity 95.0%; Pred. No. 1.9e-08;
 Matches 57; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1 qacatcagcagggcccccagagagcccttcgcgcgactacgtgagccactcttcaaac 60
 DB 841 qacatcagcagggcccccagagagcccttcgcgcgactacgtgagccactcttcaaac 466
 RESULT 7
 AA009487
 AC AC
 DI 10-SEP-2001 (first entry)
 XX Human immunodeficiency virus A (HIV A) gene.
 DE
 XX Human immunodeficiency virus A; HIV A; immunogen; anti-HIV vaccine;
 EW also therapy; fusion protein, modified vaccinia virus Ankara vector;
 EW MVA; cytotoxic T-lymphocyte; CTL; epitope; ds.
 XX
 OS Human immunodeficiency virus.
 XX
 FH Key Location/Qualifiers
 FT CDS 19..1602
 FT /*tag- a
 FT /product= "HIV A immunogen"
 XX
 XX W0200147955-AZ.
 XX
 XX 05-JUL-2001.
 XX
 XX 22-DEC-2000; 2000W0-GB04984.
 XX
 XX 23-DEC-1999; 9903B-0030294.
 XX 14-OCT-2000; 2000C3B-0025234.
 XX
 XX (MEDI) MEDICAL RES COUNCIL.
 PA (ITAL-) INT AIDS VACCINE INITIATIVE.
 PA (UYN-) UNIV NAIROBI.
 XX
 PI Hanke T., McMichael AJ;
 XX
 DE WP1: 2001.419231/44.
 DE p.espr: AAP04825.
 XX
 PT Novel immunogen for stimulating anti-HIV immune response, has a portion
 PT of gag protein of HIV from HIV clade, parts of p17, p24 and synthetic
 PT polypeptide comprising human cytotoxic T lymphocyte epitopes of HIV
 PT protein .
 XX
 XX Claim 29; Fig 2A; 65pp; English.
 PS
 XX The invention relates to a human immunodeficiency virus immunogen and
 CC their corresponding DNA molecules. An immunogen comprises a portion of
 CC gag protein of HIV from an HIV clade, parts of p17 and p24, modified to
 CC prevent R bacterial myristylation, and a synthetic polypeptide comprising
 CC human cytotoxic T-lymphocyte (CTL) epitopes of HIV protein. This
 CC immunogen is destined to elicit an HIV specific immune response in
 CC humans. The immunogen is useful in the preparation of a medicament such
 CC as vaccine to prevent or treat HIV infection in a human subject.
 CC The invention also relates to method of stimulating anti-HIV immune
 CC response in a human subject which comprises administering one or more
 CC times an amount of nucleic acid molecule sufficient to prime an immune
 CC response to the immunogen, or else may be prepared within a delivery
 CC means, such as a modified vaccinia virus Ankara (MVA) to boost the immune
 CC response to certain portion of the immunogens. The present DNA sequence
 CC encodes human immunodeficiency virus A immunogen (HIV A) fusion protein
 CC construct. HIV A immunogen consists of about 73% of gag protein fused to
 CC a string of 25 partially overlapping human CTL epitopes. The gag domain
 CC of HIV A contains p24 and p17 in an order reversed to the viral gag
 CC p17 p24-p15 polypeptide.
 XX
 SQ Sequence 1608 BP; 314 A; 568 C; 458 G; 238 T; 0 other;
 Query Match 92.0%; Score 55.2; PP 22; Length 1609;
 Best Local Similarity 95.0%; Pred. No. 1.9e-08;
 Matches 57; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1 qacatcagcagggcccccagagagcccttcgcgcgactacgtgagccactcttcaaac 60
 DB 472 qacatcagcagggcccccagagagcccttcgcgcgactacgtgagccactcttcaaac 541
 RESULT 8
 AA009488
 ID AA009488 standard; DNA; 1914 BP.
 XX
 AC AA009488;
 XX
 XX 10-SEP-2001 (first entry)
 XX
 DE Human immunodeficiency virus 1A (HIV 1A) gene.
 XX
 XX Human immunodeficiency virus 1A; HIV 1A; immunogen; anti-HIV vaccine;
 EW also therapy; fusion protein, modified vaccinia virus Ankara vector;
 EW MVA; cytotoxic T-lymphocyte; CTL; epitope; ds.
 XX
 OS Human immunodeficiency virus.
 XX
 FH Key Location/Qualifiers
 FT CDS 14..1914
 FT /*tag- d
 FT /product= "HIV 1A immunogen"
 XX
 XX W0200147955-AZ.
 XX
 XX 05-JUL-2001.
 XX
 XX 22-DEC-2000; 2000W0-GB04984.
 XX
 XX 23-DEC-1999; 9903B-0030294.
 XX 14-OCT-2000; 2000C3B-0025234.
 XX
 XX (MEDI) MEDICAL RES COUNCIL.
 PA (ITAL-) INT AIDS VACCINE INITIATIVE.
 PA (UYN-) UNIV NAIROBI.
 XX
 PI Hanke T., McMichael AJ;
 XX

PR 31-DEC-1998; 98US-0114495.
 PR 01-DEC-1999; 99US-0168471.
 XX
 XX (CHIR) CHIRON CORP.
 XX
 XX Barnett S., Zur Megede J., Srivastava I., Lian Y., Bartoe K., Liu H;
 XX Greer C., Selby M., Walker C;
 XX WPI: 2000-452400/39.
 UR
 XX Expression cassettes encoding the human immunodeficiency virus (HIV)
 XX Gag-containing polypeptide useful for vaccinating against HIV
 XX infections and acquired immunodeficiency syndrome (AIDS) -
 XX Claim 3; Fig 7; 391pp; English.
 XX
 XX The present sequence is the coding sequence of a HIV Gag expression
 XX cassette, Gag.ModS2. The Gag protein of HIV is needed for the assembly
 XX of virus-like particles. In addition, the Gag protein is involved in
 XX many stages of the HIV life cycle, including assembly, viral maturation,
 XX after particle release and early post-entry steps in viral replication.
 XX The expression cassette may be used for the recombinant expression of
 XX HIV Gag-polypeptides which may then be used to vaccinate against HIV
 XX infection and acquired immunodeficiency syndrome (AIDS).
 XX
 XX Sequence 1515 BP; 329 A; 547 C; 480 G; 159 T; 0 other;

Query Match 89.3%; Score 53.6; DB 21; Length 1515;
 Best Local Similarity 93.3%; Pred. No 60-08;
 Matches 56; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 gaatcaagcagcagcccaagagcccttcgcgaactatgaaacgtctcttcaaac 60
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 862 gaatcccccagggcccacagagcccttcgcgaactatgaaacgtctcttcaaac 921

RESULT 15
 AAA70413
 ID AAA70413 standard; DNA; 1853 BP.
 XX
 XX AC AAA70413;
 XX
 XX DT 28-NOV-2000 (first entry)
 XX
 XX DE HIV Gag-protease expression cassette coding sequence GagProt.ModS.
 XX
 XX KW HIV-1; AIDS; Gag-protease, vaccine, expression cassette; ss.
 XX
 XX OS Human immunodeficiency virus type 1.
 XX Synthetic.
 XX
 XX PN WC200039302-A2.
 XX
 XX PD 06-JUL-2000.
 XX
 XX PF 30-DEC-1999; 99WO-US31245.
 XX
 XX PR 31-DEC-1998; 98US-0114495.
 XX
 XX PR 01-DEC-1999; 99US-0168471.
 XX
 XX (CHIR) CHIRON CORP.
 XX
 XX Barnett S., Zur Megede J., Srivastava I., Lian Y., Bartoe K., Liu H;
 XX Greer C., Selby M., Walker C;
 XX WPI: 2000-452400/39.
 XX
 XX Expression cassettes encoding the human immunodeficiency virus (HIV)
 XX Gag-containing polypeptide useful for vaccinating against HIV
 XX infections and acquired immunodeficiency syndrome (AIDS) -
 XX Claim 5; Fig 7; 391pp; English.

XX The present sequence is the coding sequence of a HIV Gag-protease
 XX expression cassette, GagProt.ModS. The Gag protein of HIV is needed for
 XX the assembly of virus like particles. In addition, the Gag protein is
 XX involved in many stages of the HIV life cycle, including assembly, viral
 XX maturation after particle release and early post-entry steps in viral
 XX replication. The expression cassette may be used for the recombinant
 XX expression of HIV Gag polypeptides which may then be used to vaccinate
 XX against HIV infection and acquired immunodeficiency syndrome (AIDS).
 XX
 XX Sequence 1853 BP; 421 A; 624 C; 580 G; 228 T; 0 other;

Query Match 89.3%; Score 53.6; DB 21; Length 1853;
 Best Local Similarity 93.3%; Pred. No. 6.2e-08;
 Matches 56; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 gaatcaagcagcagcccaagagcccttcgcgaactatgaaacgtctcttcaaac 60
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 862 gaatcccccagggcccacagagcccttcgcgaactatgaaacgtctcttcaaac 921

Search completed: July 2, 2002, 23:09:45
 Job Time: 8497 sec



High quality sequence start: 2
High quality sequence stop: 141
polyA yes.

FEATURES Location/Qualifiers

Source

1..148

Organization "Sorghum propinquum"

Z6 xref: "taxon:12711"

Z6 xref: "Phorbol-Induced Meristem 1 (PIM1)"

Z6 xref: "Phorbol-Induced meristem1 Vector"

Phorbol-Induced Meristem 1 (PIM1) Site 2:

Phorbol-Induced Meristem 1 (PIM1) Site 1:

Phorbol-Induced Meristem 1 (PIM1) Site 2:

Phorbol-Induced Meristem 1 (PIM1) Site 3:

Phorbol-Induced Meristem 1 (PIM1) Site 4:

Phorbol-Induced Meristem 1 (PIM1) Site 5:

Phorbol-Induced Meristem 1 (PIM1) Site 6:

Phorbol-Induced Meristem 1 (PIM1) Site 7:

Phorbol-Induced Meristem 1 (PIM1) Site 8:

Phorbol-Induced Meristem 1 (PIM1) Site 9:

Phorbol-Induced Meristem 1 (PIM1) Site 10:

Phorbol-Induced Meristem 1 (PIM1) Site 11:

Phorbol-Induced Meristem 1 (PIM1) Site 12:

Phorbol-Induced Meristem 1 (PIM1) Site 13:

Phorbol-Induced Meristem 1 (PIM1) Site 14:

Phorbol-Induced Meristem 1 (PIM1) Site 15:

Phorbol-Induced Meristem 1 (PIM1) Site 16:

Phorbol-Induced Meristem 1 (PIM1) Site 17:

Phorbol-Induced Meristem 1 (PIM1) Site 18:

Phorbol-Induced Meristem 1 (PIM1) Site 19:

Phorbol-Induced Meristem 1 (PIM1) Site 20:

Phorbol-Induced Meristem 1 (PIM1) Site 21:

Phorbol-Induced Meristem 1 (PIM1) Site 22:

Phorbol-Induced Meristem 1 (PIM1) Site 23:

Phorbol-Induced Meristem 1 (PIM1) Site 24:

Phorbol-Induced Meristem 1 (PIM1) Site 25:

Phorbol-Induced Meristem 1 (PIM1) Site 26:

Phorbol-Induced Meristem 1 (PIM1) Site 27:

Phorbol-Induced Meristem 1 (PIM1) Site 28:

Phorbol-Induced Meristem 1 (PIM1) Site 29:

Phorbol-Induced Meristem 1 (PIM1) Site 30:

Phorbol-Induced Meristem 1 (PIM1) Site 31:

Phorbol-Induced Meristem 1 (PIM1) Site 32:

Phorbol-Induced Meristem 1 (PIM1) Site 33:

Phorbol-Induced Meristem 1 (PIM1) Site 34:

Phorbol-Induced Meristem 1 (PIM1) Site 35:

Phorbol-Induced Meristem 1 (PIM1) Site 36:

Phorbol-Induced Meristem 1 (PIM1) Site 37:

Phorbol-Induced Meristem 1 (PIM1) Site 38:

Phorbol-Induced Meristem 1 (PIM1) Site 39:

Phorbol-Induced Meristem 1 (PIM1) Site 40:

Phorbol-Induced Meristem 1 (PIM1) Site 41:

Phorbol-Induced Meristem 1 (PIM1) Site 42:

Phorbol-Induced Meristem 1 (PIM1) Site 43:

Phorbol-Induced Meristem 1 (PIM1) Site 44:

Phorbol-Induced Meristem 1 (PIM1) Site 45:

Phorbol-Induced Meristem 1 (PIM1) Site 46:

Phorbol-Induced Meristem 1 (PIM1) Site 47:

Phorbol-Induced Meristem 1 (PIM1) Site 48:

Phorbol-Induced Meristem 1 (PIM1) Site 49:

Phorbol-Induced Meristem 1 (PIM1) Site 50:

Phorbol-Induced Meristem 1 (PIM1) Site 51:

Phorbol-Induced Meristem 1 (PIM1) Site 52:

Phorbol-Induced Meristem 1 (PIM1) Site 53:

Phorbol-Induced Meristem 1 (PIM1) Site 54:

Phorbol-Induced Meristem 1 (PIM1) Site 55:

Phorbol-Induced Meristem 1 (PIM1) Site 56:

Phorbol-Induced Meristem 1 (PIM1) Site 57:

Phorbol-Induced Meristem 1 (PIM1) Site 58:

Phorbol-Induced Meristem 1 (PIM1) Site 59:

Phorbol-Induced Meristem 1 (PIM1) Site 60:

Phorbol-Induced Meristem 1 (PIM1) Site 61:

Phorbol-Induced Meristem 1 (PIM1) Site 62:

Phorbol-Induced Meristem 1 (PIM1) Site 63:

Phorbol-Induced Meristem 1 (PIM1) Site 64:

Phorbol-Induced Meristem 1 (PIM1) Site 65:

Phorbol-Induced Meristem 1 (PIM1) Site 66:

Phorbol-Induced Meristem 1 (PIM1) Site 67:

Phorbol-Induced Meristem 1 (PIM1) Site 68:

Phorbol-Induced Meristem 1 (PIM1) Site 69:

Phorbol-Induced Meristem 1 (PIM1) Site 70:

Phorbol-Induced Meristem 1 (PIM1) Site 71:

Phorbol-Induced Meristem 1 (PIM1) Site 72:

QUALITY

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

QUALITY

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

QUALITY

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1



Copyright (c) 1995 Zom Computer Ltd.

Sequence version 4.5

om nucleic nucleic search, using sw model

Run on: July 2, 2002, 19:45:13 ; Search time 64.61 seconds

(without alignments)

251,693 alignment cell updates/sec

Hit(s): US 09 475-704-1

Port(s) score: 60

Sequence: 1 spent on alignment procedure.....104 accepted residues 60

Search table: HERNILLY RNP

Gap: 10.0 ; Gap: 1.6

Searches: 60533 seqs, 12261652 residues

Total number of hits satisfying chosen parameters: 76766

Minimum hit seq length: 0

Maximum hit seq length: 2000000

Post processing: Minimum Match 100

Listed first 45 summaries

Database: Issued_Patent_SNA:
 1 350 3 9207 3 US-08-388-353 800
 2 350 3 9207 3 US-08-388-353 800
 3 350 3 9207 3 US-08-388-353 800
 4 350 3 9207 3 US-08-388-353 800
 5 350 3 9207 3 US-08-388-353 800
 6 350 3 9207 3 US-08-388-353 800
 7 350 3 9207 3 US-08-388-353 800
 8 350 3 9207 3 US-08-388-353 800
 9 350 3 9207 3 US-08-388-353 800
 10 350 3 9207 3 US-08-388-353 800

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	BB	ID	Description
1	45	58.3	9207	3	US-08-388-353 800	Sequence 800, App
2	45	58.3	9207	3	US-08-388-353 800	Sequence 800, App
3	45	55.7	718	6	6294259 2	Patent No. 6294259
4	45	55.7	796	6	6294259 4	Patent No. 6294259
5	45	55.7	796	6	6294259 5	Patent No. 6294259
6	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
7	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
8	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
9	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
10	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
11	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
12	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
13	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
14	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
15	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
16	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
17	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
18	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
19	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
20	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
21	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
22	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
23	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
24	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
25	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
26	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11
27	45	55.7	845	1	US-08-388-353 800	Sequence 3, App11

28	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
29	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
30	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
31	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
32	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
33	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
34	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
35	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
36	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
37	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
38	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
39	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
40	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
41	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
42	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
43	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
44	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11
45	45.4	55.7	9236	2	US-08-388-353 800	Sequence 3, App11

RESULT 1

US-08-388-353 800
 Patent No. 6010865

GENERAL INFORMATION:

APPLICANT: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ATTORNEY: Boehringer-Ingelheim

ALIGNMENTS

Query Match: 58.3% Score: 95.1% ID: 3, Local: 9207
 Best Local Similarity: 74.6% Prod. No. 0.0004
 Matches: 44, Conserved: 15, Mismatches: 15, Gaps: 0

Query Match 100.0%; Score 60; DB 6; Length 1608;
 Best Local Similarity 100.0%; Pred. No. 7.5e-07;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 gacatccgcagagcccttcgcgactactgaacgctcttccaaagac 60
 |||||
 DB 472 GACATCCGCAGAGCCCTTCGCGACTACTGAACGCTCTTCCAAAGAC 533

RESULT 2
 LOCUS AX188560 1914 bp DNA linear PAT 08-AUG-2001
 DEFINITION Sequence 29 from Patent WO0147955.
 ACCESSION AX188560
 VERSION AX188560.1 GI:15142200
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct.
 artificial sequence.
 REFERENCE 1 (bases 1 to 1914)
 Hanks,T.M. and Memmichael,A.J.
 TITLE Improvements in or relating to immune responses to hiv
 JOURNAL Patent: WO 0147955-A 29 05-JUL-2001;
 MEDICAL RESEARCH COUNCIL (GB) ; International Aids Vaccine
 Initiative (US) ; University of Nairobi (KE)
 FEATURES
 source
 1. 1914
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="chimeric polynucleotide"
 BASE COUNT 383 a 728 c 534 g 269 t
 ORIGIN

Query Match 100.0%; Score 60; DB 6; Length 1914;
 Best Local Similarity 100.0%; Pred. No. 7.3e-07;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 gacatccgcagagcccttcgcgactactgaacgctcttccaaagac 60
 |||||
 DB 456 GACATCCGCAGAGCCCTTCGCGACTACTGAACGCTCTTCCAAAGAC 525

RESULT 3
 LOCUS AX188562 2493 bp DNA linear PAT 09-AUG-2001
 DEFINITION Sequence 31 from Patent WO0147955.
 ACCESSION AX188562
 VERSION AX188562.1 GI:15142201
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct.
 artificial sequence.
 REFERENCE 1 (bases 1 to 2493)
 Hanks,T.M. and Memmichael,A.J.
 TITLE Improvements in or relating to immune responses to hiv
 JOURNAL Patent: WO 0147955-A 31 05-JUL-2001;
 MEDICAL RESEARCH COUNCIL (GB) ; International Aids Vaccine
 Initiative (US) ; University of Nairobi (KE)
 FEATURES
 source
 1. 2493
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="chimeric polynucleotide"
 BASE COUNT 516 a 887 c 685 g 455 t
 ORIGIN

Query Match 100.0%; Score 60; DB 6; Length 2493;
 Best Local Similarity 100.0%; Pred. No. 6.9e-07;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 gacatccgcagagcccttcgcgactactgaacgctcttccaaagac 60
 |||||
 DB 456 GACATCCGCAGAGCCCTTCGCGACTACTGAACGCTCTTCCAAAGAC 525

RESULT 4
 LOCUS AX188564 4450 bp DNA linear PAT 08-AUG-2001
 DEFINITION Sequence 44 from Patent WO0147955.
 ACCESSION AX188564
 VERSION AX188564.1 GI:15142202
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct.
 artificial sequence.
 REFERENCE 1 (bases 1 to 4450)
 Hanks,T.M. and Memmichael,A.J.
 TITLE Improvements in or relating to immune responses to hiv
 JOURNAL Patent: WO 0147955-A 44 05-JUL-2001;
 MEDICAL RESEARCH COUNCIL (GB) ; International Aids Vaccine
 Initiative (US) ; University of Nairobi (KE)
 FEATURES
 source
 1. 4450
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="chimeric polynucleotide"
 BASE COUNT 888 a 1640 c 1259 g 573 t
 ORIGIN

Query Match 100.0%; Score 60; DB 6; Length 4450;
 Best Local Similarity 100.0%; Pred. No. 6.3e-07;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 gacatccgcagagcccttcgcgactactgaacgctcttccaaagac 60
 |||||
 DB 466 GACATCCGCAGAGCCCTTCGCGACTACTGAACGCTCTTCCAAAGAC 525

RESULT 5
 LOCUS AF201927 3509 bp DNA linear SVN 16-MAR-2000
 DEFINITION Synthetic construct gag protein gene, complete cds.
 ACCESSION AF201927
 VERSION AF201927.1 GI:7248702
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct.
 artificial sequence.
 REFERENCE 1 (bases 1 to 3509)
 zur Meckede,J., Chen,M.C., Doe,B., Schaefer,M., Greer,C.E.,
 Selby,M., Otton,G.R. and Barnett,S.W.
 TITLE Increased expression and immunogenicity of sequence-modified human
 immunodeficiency virus type 1 gag gene
 JOURNAL J. Virol. 74 (6), 2628-2635 (2000)
 MEDLINE 20148954
 PubMed 10684277
 REFERENCE 2 (bases 1 to 1509)
 zur Meckede,J. and Barnett,S.W.
 TITLE Direct Submission
 JOURNAL Submitted (01-NOV-1999) Vaccines, Chiron Corporation, 4560 Horton,
 Emeryville, CA 94608, USA
 FEATURES
 source
 1. 3509
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="HIV-1SF2 p55gag"
 /codon_start=1
 /translation=1
 /product="gag protein"
 /protein_id="AA043628.1"

[illegible]

850 GACATCCGCCAAGGCCCGAAGGAAACCTTTCGGGACTACGTGGACCGTTCTACAAAAC 908

Job time: 8953 sec

RESULTS

AX283597	LOCUS	AX283597	4307 bp	ENA	linear	PAT 20-NOV-2001
	DEFINITION	Sequence	15 from Patent WO0179518.			
	ACCESSION	AX283597				
	VERSION	AX283597.1	GI:17044323			

KEYWORDS: synthetic construct.
SOURCE: synthetic construct.
ORGANISM: synthetic construct.

artificial sequence.

REFERENCE
AUTHORS
1 (sites)
Kingsman, A. J., Kim, N. T., Kotsopoulou, E. E., Rohll, J., and
Mitrophanous, K. A.

TITLE	Method
1. The effect of temperature on the rate of reaction of hydrogen peroxide with potassium iodide	1. The effect of temperature on the rate of reaction of hydrogen peroxide with potassium iodide
2. The effect of concentration on the rate of reaction of hydrogen peroxide with potassium iodide	2. The effect of concentration on the rate of reaction of hydrogen peroxide with potassium iodide
3. The effect of catalyst on the rate of reaction of hydrogen peroxide with potassium iodide	3. The effect of catalyst on the rate of reaction of hydrogen peroxide with potassium iodide
4. The effect of pH on the rate of reaction of hydrogen peroxide with potassium iodide	4. The effect of pH on the rate of reaction of hydrogen peroxide with potassium iodide
5. The effect of surface area on the rate of reaction of hydrogen peroxide with potassium iodide	5. The effect of surface area on the rate of reaction of hydrogen peroxide with potassium iodide
6. The effect of pressure on the rate of reaction of hydrogen peroxide with potassium iodide	6. The effect of pressure on the rate of reaction of hydrogen peroxide with potassium iodide
7. The effect of solvent on the rate of reaction of hydrogen peroxide with potassium iodide	7. The effect of solvent on the rate of reaction of hydrogen peroxide with potassium iodide
8. The effect of ionic strength on the rate of reaction of hydrogen peroxide with potassium iodide	8. The effect of ionic strength on the rate of reaction of hydrogen peroxide with potassium iodide
9. The effect of dielectric constant on the rate of reaction of hydrogen peroxide with potassium iodide	9. The effect of dielectric constant on the rate of reaction of hydrogen peroxide with potassium iodide
10. The effect of viscosity on the rate of reaction of hydrogen peroxide with potassium iodide	10. The effect of viscosity on the rate of reaction of hydrogen peroxide with potassium iodide

JOURNAL Patent: WO 0179518-A 15 25-OCT-2001;

Oxford Biomedica (UK) Limited (GB)

FEATURES

source 1. .4307

forqatish "synthetic construct"

/db_xref="taxon:32630"

Today's All-Postcard Defection

BASE COUNT	1137 a	1192 c	1286 g	693 f
BASE COUNT	1137 a	1192 c	1286 g	693 f

ORIGIN

Query Match:	79.78:	Score 47.8:	DB 6:	Length 4307:
--------------	--------	-------------	-------	--------------

Best Local Similarity 88.1%; Pred. No. 0.0014;

Matches 52; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

(v) $\mathcal{L}(\mathcal{A})$ is a \mathcal{C}^* -algebra.

RESULT 15

RG50.1	E3
AX283607	
LOCUS	AX283607 4307 bp DNA
DEFINITION	Sequence 25 from Patent WO0179518.
ACCESSION	AX283607
VERSION	AX283607.1 GI:17044333
	linear PAT 20-NW-2001

KEYWORDS	.	synthetic construct.
SOURCE		synthetic construct
ORGANISM		synthetic construct

artificial sequence.

REFERENCE
1 (sites)
AUTHORS
Kingsman, A. J., Kim, N. T., Kotsopoulou, E. E., Rohll, J., and
Mitrobanous, K. A.

TITLE	Method
Size of program as % of m.	

JOURNAL OF POLYMER SCIENCE: PART A: POLYMER CHEMISTRY
Patent: WO 0174518-A 25 25 OCT 2001;

Oxford Biomedica (UK) Limited (GB)

FEATURES

1. 4307
source

/organism- "synthetic construct"

```
/db_xref-"taxon:32630"
```

/note: "Codon optimised qaq-pol sequence (pSYNGP)"

BASE COUNT	1137 a	1192 c	1286 q	692 t
------------	--------	--------	--------	-------

ORIGIN

Query Match 79.7%: score 47.8: DB 6: Length 4307:

Best local similarity 88.1%: Pred. No. 0.0014:

Matches	Conservative	Mismatches	Indels	Gaps
50	25	0	7	0

[illegible]

Search completed: July 2, 2002, 21:57:36

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

[illegible][illegible]

[illegible]

Search completed: July 4, 2002, 21:59:00
Log file: 0027305

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

PT especially human against HIV

XX Claim 1: Page 92: 113pp: English.

PS Expression cassettes comprising a polynucleotide encoding antigenic

XX type C human immunodeficiency virus (HIV) Gag or Env polypeptides are

CC useful in DNA immunization, generation of packaging cell lines and

CC production of Gag and/or Env containing proteins. Synthetic Env and Gag

CC expression cassettes exhibit increased potency for induction of

CC cytotoxic T-lymphocyte (CTL) responses by DNA immunization. Gag of HIV-1

CC self-assemble into non-infectious virus-like particles which are used as

CC a matrix for the proper presentation of an antigen entrapped or

CC associated to the immune system of the host.

XX Sequence 60 BP: 12 A; 24 C; 15 G; 9 T; 0 other;

SQ

Query Match 100.0%; Score 60; DB 21; Length 60;

Best Local Similarity 100.0%; Prod. No. 2b-09;

Matches 60; Conservation 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 qacatccacagagcccaagagccctccgcagactgagacagctctctcaaacac 60

DB 1 qacatccacagagcccaagagccctccgcagactgagacagctctctcaaacac 60

RESULT 2

AAA51610

ID AAA51610 standard; DNA; 1509 BP.

XX

AC AAA51610;

XX

DT 31-OCT-2000 (first entry)

XX

DE HIV synthetic Gag polynucleotide.

XX

KW Gag, expression cassette, antigenic, type C, HIV, Env, synthetic,

KW DNA immunization; packaging cell line, antigen presentation, ss.

XX

OS Human immunodeficiency virus type C strain AF110967

OS Synthetic.

XX

PN WC200039304-A2.

XX

PD 06-JUL-2000.

XX

PF 30-DEC-1999; 99WO-US31273.

XX

PR 31 DEC 1998; 98US-0114495.

PR 01-SEP-1999; 99US-0152195.

XX

PA (CHIR) CHIRON CORP.

XX

PI Barnett S. Zur Meade J.

XX

DR WPI: 2000-452401/39.

XX

PT Polynucleotide encoding antigenic type C HIV Gag polypeptide or a HIV

PT Env polypeptide and the polypeptide useful for immunizing a mammal

PT especially human against HIV

XX

PS Claim 2: Page 93: 113pp: English.

XX

PS Expression cassettes comprising a polynucleotide encoding antigenic

XX type C human immunodeficiency virus (HIV) Gag or Env polypeptides are

CC useful in DNA immunization, generation of packaging cell lines and

CC production of Gag and/or Env containing proteins. Synthetic Env and Gag

CC expression cassettes exhibit increased potency for induction of

CC cytotoxic T-lymphocyte (CTL) responses by DNA immunization. Gag of HIV-1

CC self-assemble into non-infectious virus-like particles which are used as

CC a matrix for the proper presentation of an antigen entrapped or

CC associated to the immune system of the host.

XX

SQ Sequence 1509 BP: 320 A; 556 C; 472 G; 161 T; 0 other;

Query Match 100.0%; Score 60; DB 21; Length 1509;

Best Local Similarity 100.0%; Prod. No. 2.4e-09;

Matches 60; Conservation 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 qacatccacagagcccaagagccctccgcagactgagacagctctctcaaacac 60

DB 841 qacatccacagagcccaagagccctccgcagactgagacagctctctcaaacac 900

RESULT 3

AAA51626

ID AAA51626 standard; DNA; 1509 BP.

XX

AC AAA51626;

XX

DT 31-OCT-2000 (first entry)

XX

DE HIV codon optimized synthetic gag polynucleotide.

XX

KW Gag, expression cassette; antigenic; type C; HIV; Env; synthetic;

KW DNA immunization; packaging cell line; antigen presentation; ss.

XX

OS Human immunodeficiency virus type C strain AF110967.

OS Synthetic.

XX

PN WC200039304-A2.

XX

PD 06-JUL-2000.

XX

PF 30-DEC-1999; 99WO-US31273.

XX

PR 31 DEC 1998; 98US-0114495.

PR 01-SEP-1999; 99US-0152195.

XX

PA (CHIR) CHIRON CORP.

XX

PI Barnett S. Zur Meade J.

XX

DR WPI: 2000-452401/39.

XX

PT Polynucleotide encoding antigenic type C HIV Gag polypeptide or a HIV

PT Env polypeptide and the polypeptide useful for immunizing a mammal

PT especially human against HIV

XX

PS Disclosure: Page 104; 113pp: English.

XX

PS Expression cassettes comprising a polynucleotide encoding antigenic

XX type C human immunodeficiency virus (HIV) Gag or Env polypeptides are

CC useful in DNA immunization, generation of packaging cell lines and

CC production of Gag and/or Env containing proteins. Synthetic Env and Gag

CC expression cassettes exhibit increased potency for induction of

CC cytotoxic T-lymphocyte (CTL) responses by DNA immunization. Gag of HIV-1

CC self-assemble into non-infectious virus-like particles which are used as

CC a matrix for the proper presentation of an antigen entrapped or

CC associated to the immune system of the host.

XX

SQ Sequence 1509 BP: 321 A; 559 C; 471 G; 158 T; 0 other;

Query Match 100.0%; Score 60; DB 21; Length 1509;

Best Local Similarity 100.0%; Prod. No. 2.4e-09;

Matches 60; Conservation 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 qacatccacagagcccaagagccctccgcagactgagacagctctctcaaacac 60

DB 841 qacatccacagagcccaagagccctccgcagactgagacagctctctcaaacac 900

RESULT 4

AA109487

[illegible]


```

10 AAA7041% standard; DNA; 1453 bp.
A7 AAA7041%
XX
11 26 Nov 2000 (first entry)
DE HIV GAG protease expression cassette coding sequence GAGProt_Med5.
XX
12 HIV-1; AIDS; GAG protease; vaccine; expression cassette; ss.
XX
13 Human immunodeficiency virus type 1.
XX
14 Synthesized.
XX
15 W0200049402 A2.
XX
16 06 Jul 2000.
XX
17 30 Dec 1999; 99W01051245.
XX
18 31 Dec 1999; 99US 0114495.
19 01 Dec 1999; 99US 0168471.
XX
20 (CHIR) CHIRON Corp.
XX
21 Barnett S, Zur Meede J, Shrivastava L, Lim Y, Bartok K, Lin H,
22 Greer C, Selby M, Walker C.
XX
23 WPI; 2000-452400/09.
XX
24 Expression cassettes encoding the human immunodeficiency virus (HIV)
25 GAG containing polypeptide useful for vaccinating against HIV
26 infections and acquired immunodeficiency syndrome (AIDS).
XX
27 claim 5; Fig 7; 61pp; English.
XX
28 The present sequence is the coding sequence of a HIV GAG protease
29 expression cassette. GAGProt_Med5. The GAG protein of HIV is needed for
30 the assembly of virus-like particles. In addition, the GAG protein is
31 involved in many stages of the HIV life cycle, including assembly, virus
32 maturation after particle release and early post entry steps in viral
33 replication. The expression cassette may be used for the recombinant
34 expression of HIV GAG polypeptides which may then be used to vaccinate
35 against HIV infection and acquired immunodeficiency syndrome (AIDS).
XX
36 Sequence 1865 bp; 421 A; 624 C; 580 G; 228 T; 6 other.
XX
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295
2296
2297
2298
2299
2300
2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
2373
2374
2375
2376
2377
2378
2379
2380
2381
2382
2383
2384
2385
2386
2387
2388
2389
2390
2391
2392
2393
2394
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
2428
2429
2430
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
2441
2442
2443
2444
2445
2446
2447
2448
2449
2450
2451
2452
2453
2454
2455
2456
2457
2458
2459
2460
2461
2462
2463
2464
2465
2466
2467
2468
2469
2470
2471
2472
2473
2474
2475
2476
2477
2478
2479
2480
2481
2482
2483
2484
2485
2486
2487
2488
2489
2490
2491
2492
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523
2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
2541
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
2552
2553
2554
2555
2556
2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569
2570
2571
2572
2573
2574
2575

```

PI Expression cassettes encoding the human immunodeficiency virus (HIV)
 PI Gag-containing polypeptide useful for vaccinating against HIV
 PI Infections and acquired immunodeficiency syndrome (AIDS) -
 XX
 XX Claim 5; Fig 70; 39lpp; English.
 PS
 CC The present sequence is the coding sequence of a HIV Gag-protease
 CC expression cassette, GAGProMod.SF2(GP2). The Gag protein of HIV is
 CC needed for the assembly of virus like particles. In addition, the Gag
 CC protein is involved in many stages of the HIV life cycle, including
 CC assembly, virion maturation after particle release and early post-entry
 CC steps in viral replication. The expression cassette may be used for the
 CC recombinant expression of HIV Gag-polypeptides which may then be used to
 CC vaccinate against HIV infection and acquired immunodeficiency syndrome
 CC (AIDS).
 XX
 XX Sequence: 1865 BP; 460 A; 583 C; 569 G; 253 T; 0 other;
 SQ

Query Match 97.38; Score 58.4; DB 21; Length 1865;
 Best Local Similarity 98.38; Pred. No. 7.6e-09;
 Matches 59; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 gacatccacgagggcccaagaaagcccttcggactactatgacagcttctcaagacc 60
 DB 868 gacatccacgagggcccaagaaagcccttcggactactatgacagcttctcaagacc 927
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 15
 AAA70415
 ID AAA70415 standard; DNA; 2031 BP.
 AC AAA70415;
 XX
 XX 28-NOV-2000 (first entry)
 DT
 DE Synthetic HIV Gag/RTV core fusion coding sequence.
 DE
 XX HIV-1; AIDS; Gag; vaccine; expression cassette; ss.
 KW
 XX Chimeric - Human immunodeficiency virus type 1.
 OS Chimeric - Hepatitis C virus.
 OS
 XX W0200049302-A2.
 PN
 XX 06-JUL-2000.
 PD
 XX 30-DEC-1999; 99WO-US31245.
 PF
 XX 31-DEC-1998; 98US-0114495.
 PR 01-DEC-1999; 99US-0168471.
 PR
 XX (CHIR) CHIRON CORP.
 PA
 XX Barnett S, Zar Medve J, Srinastara I, Lian Y, Hartog K, Liu H;
 PI Greer C, Selby M, Walker C;
 PI WPI, 2000 452430/39.
 UR
 XX
 XX Expression cassettes encoding the human immunodeficiency virus (HIV)
 PI Gag-containing polypeptide useful for vaccinating against HIV
 PI Infections and acquired immunodeficiency syndrome (AIDS) -
 XX
 XX Example 1; Pages 341-342; 39lpp; English.
 PS
 PS The present sequence is a HIV Gag/Hepatitis C virus (HCV) core fusion
 CC coding sequence. The Gag protein of HIV is needed for the assembly of
 CC virus like particles. In addition, the Gag protein is involved in many
 CC stages of the HIV life cycle, including assembly, virion maturation after
 CC particle release and early post-entry steps in viral replication. The
 CC present invention relates to synthetic HIV Gag expression cassettes. The
 CC present sequence was cloned and used to generate the expression cassettes
 CC of the present invention. The expression cassettes may be used for the

CC recombinant expression of HIV Gag-polypeptides which may then be used to
 CC vaccinate against HIV infection and acquired immunodeficiency syndrome
 CC (AIDS).
 XX
 XX Sequence 2041 BP; 421 A; 707 C; 646 G; 257 T; 0 other;
 SQ

Query Match 97.38; Score 58.4; DB 21; Length 2041;
 Best Local Similarity 98.38; Pred. No. 7.6e-09;
 Matches 59; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 gacatccacgagggcccaagaaagcccttcggactactatgacagcttctcaagacc 60
 DB 862 gacatccacgagggcccaagaaagcccttcggactactatgacagcttctcaagacc 921
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Search completed: July 2, 2002, 24:09:46
 Job time: 8498 sec

The first part of the paper discusses the importance of the study of the history of the United States. It is argued that the study of history is essential for a full understanding of the present. The second part of the paper discusses the importance of the study of the history of the United States. It is argued that the study of history is essential for a full understanding of the present. The third part of the paper discusses the importance of the study of the history of the United States. It is argued that the study of history is essential for a full understanding of the present.